Close Menu

EGFR Biomarkers

News and reporting on EGFR biomarkers.

This story has been updated from a previous version to include information about Biocartis' newly branded MDx platform and AACR presentation.

Researchers from Johns Hopkins have identified a marker, Mig6, that in early studies has been able to predict longer survival among patients taking the EGFR tyrosine kinase inhibitors gefitinib (Astra Zeneca's Iressa) and erlotinib (Genenetech's Tarceva).

Originally published May 14.
Smoking, most people have come to accept, is a major cause of lung cancer. But each year in the US, up to 24,000 men and women who have never smoked still end up dying from the disease.

Originally published May 7.

In the first quarter of this year, pharmacogenetically targeted cancer drugs Xalkori and Zelboraf had marked increases in revenues from the previous year's quarter.

This article has been updated from an earlier version with additional information from Qiagen on its PMA filing for an EGFR mutation companion test.

Pages

Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.

NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.

Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.